2009
Persistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial
Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 50: 176-181. PMID: 19131891, PMCID: PMC2670996, DOI: 10.1097/qai.0b013e3181938e7e.Peer-Reviewed Original ResearchConceptsSelf-administered therapyHIV-1 RNACD4 lymphocyte countVirological successDrug usersAntiretroviral therapyLymphocyte countMonths postinterventionLog10 HIV-1 RNAProportion of subjectsActive drug usersVirological benefitVirological outcomesSecondary outcomesControlled TrialsPrimary outcomeBlood samplesDAARTMultivariate analysisBenefits persistTherapyTrialsAdditional strategiesOutcomesPostintervention
2006
Impact of Enhanced Services on Virologic Outcomes in a Directly Administered Antiretroviral Therapy Trial for HIV-Infected Drug Users
Smith-Rohrberg D, Mezger J, Walton M, Bruce RD, Altice FL. Impact of Enhanced Services on Virologic Outcomes in a Directly Administered Antiretroviral Therapy Trial for HIV-Infected Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 43: s48-s53. PMID: 17133204, DOI: 10.1097/01.qai.0000248338.74943.85.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsVirologic outcomesCase management servicesDrug usersVirologic successService utilizationRNA levelsHigher medical service utilizationHIV-1 RNA reductionLog10 HIV-1 RNAAntiretroviral Therapy (SMART) trialImproved virologic outcomesHealth service utilizationHIV-1 RNASelf-administered therapyCopies/mLMedical service utilizationActive drug usersSubstance abuse servicesAntiretroviral therapyHIV outcomesPrimary outcomeProblematic adherenceTherapy trialsDAART